GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » EPS (Diluted)

Comera Life Sciences Holdings (Comera Life Sciences Holdings) EPS (Diluted) : $-0.49 (TTM As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings EPS (Diluted)?

Comera Life Sciences Holdings's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.49.

Comera Life Sciences Holdings's EPS (Basic) for the three months ended in Sep. 2023 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.49.

Comera Life Sciences Holdings's EPS without NRI for the three months ended in Sep. 2023 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.50.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Comera Life Sciences Holdings EPS (Diluted) Historical Data

The historical data trend for Comera Life Sciences Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings EPS (Diluted) Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
EPS (Diluted)
-0.11 -0.29 -1.76

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.20 -0.18 -0.13 -0.08 -0.10

Competitive Comparison of Comera Life Sciences Holdings's EPS (Diluted)

For the Biotechnology subindustry, Comera Life Sciences Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's PE Ratio falls into.



Comera Life Sciences Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Comera Life Sciences Holdings's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-18.004-0)/10.453
=-1.72

Comera Life Sciences Holdings's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.154-0)/23.113
=-0.09

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Comera Life Sciences Holdings  (OTCPK:CMRA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Comera Life Sciences Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065